8CB.F - Cannara Biotech Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.1075
-0.0030 (-2.71%)
At close: 8:12AM CEST
Stock chart is not supported by your current browser
Previous Close0.1105
Open0.1075
Bid0.1100 x 0
Ask0.1190 x 0
Day's Range0.1075 - 0.1075
52 Week Range0.0794 - 0.1800
Volume2,250
Avg. Volume497
Market Cap81.058M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    Cannara Biotech Secures $6 Million Mortgage Financing Facility with Canadian Imperial Bank of Commerce

    Cannara Biotech Secures $6 Million Mortgage Financing Facility with Canadian Imperial Bank of Commerce

  • CNW Group

    Cannara Biotech Submits Site Evidence Package to Health Canada for its Quebec Facility

    VANCOUVER , Sept. 12, 2019 /CNW/ - Cannara Biotech Inc. ("Cannara Biotech" or the "Company") (LOVE.CN) (OTCQB:LOVFF) (8CB.F), an emerging vertically integrated cannabis company focused on indoor cultivation and sale of  premium cannabis and cannabis-infused products, announced it has submitted to Health Canada its site evidence package for Phase One of the Company's cultivation and processing facility in Farnham, Quebec . With construction recently completed, Phase One consists of 170,000 square feet, of which 110,000 is dedicated to indoor cultivation with a capacity of 20,000 kg of premium dried cannabis once the cultivation license is granted. The facility is situated on 27-acres of land located 45 minutes from Montreal and both the facility and the license are held through wholly owned subsidiaries of Cannara Biotech Inc.

  • PR Newswire

    Cannara Announces Appointment of New Chief Operating Officer

    VANCOUVER, Aug. 15, 2019 /PRNewswire/ - Cannara Biotech Inc. ("Cannara Biotech" or the "Company") (LOVE.CN) (OTCQB:LOVFF) (8CB.F), an emerging vertically integrated cannabis company focused on the cultivation and sale of dried premium cannabis and cannabis-infused products, today announced the appointment of Barry Laxer as Cannara's new Chief Operating Officer, effective August 14, 2019. "We are excited to welcome Barry to the leadership team, knowing his contributions will help accelerate our company to its next stage of growth," said Zohar Krivorot, President and CEO of Cannara. Barry will replace Evan Morris, who has helped bring the construction phase of our Farnham facility to completion.

  • CNW Group

    Live OTCQB Venture Company Investor Conference August 1st

    Live OTCQB Venture Company Investor Conference August 1st

  • CNW Group

    Cannara Biotech Inc. Reports Q3 2019 Results

    VANCOUVER , July 25, 2019 /CNW/ - Cannara Biotech ("Cannara" or the "Company") (LOVE.CN) (8CB.F) (OTCQB:LOVFF), an emerging vertically integrated cannabis company focused on the cultivation and sale of dried premium cannabis and cannabis-infused products, today announced financial results for the three month and nine month periods ended May 31, 2019. Closed a Global shopCBD.com Inc. financing in excess of $8 million to support the launch of the online e-commerce platform for the sale and distribution, in the US, of hemp-based CBD products. Subsequent to the quarter, the Company further strengthened its balance sheet with a $2.1 million private placement.

  • CNW Group

    Cannara Biotech Announces Non-Brokered Private Placement of 12,000,000 Common Shares

    Cannara Biotech Announces Non-Brokered Private Placement of 12,000,000 Common Shares

  • CNW Group

    Cannara Biotech Appoints Dr. Sara May to its Board of Directors

    VANCOUVER , May 24, 2019 /CNW/ - Cannara Biotech ("Cannara" or the "Company") (LOVE.CN) (8CB.F) (CNBTF), an emerging vertically integrated cannabis company focused on cultivation and cannabis-infused products, today announced the appointment of Dr. Sara May , PhD. Dr. May is recognized as an expert in the medical cannabis sector and will bring  additional skill sets and help strengthen  the Company's Board.

  • CNW Group

    Cannara Biotech Commences Trading on the OTCQB Market in the United States

    VANCOUVER , May 15, 2019 /CNW/ - Cannara Biotech ("Cannara" or the "Company") (LOVE.CN) (8CB.F) (CNBTF), an emerging vertically integrated cannabis company focused on the cultivation and sale of cannabis and cannabis-infused products to the Canadian and international markets, today announced its common shares are listed for trading on the OTCQB® Venture Market under the  trading symbol "CNBTF". The OTC operates financial markets for approximately 10,000 U.S. and global securities.  "Cannabis and hemp-CBD markets are global markets, with customers, vendors and investors domiciled across all major industrial nations," said Zohar Krivorot, President and CEO of Cannara.

  • GlobeNewswire

    PSIQ ANNOUNCES RESELLER AGREEMENT WITH CANNARA BIOTECH SUBSIDIARY SHOPCBD.COM TO MARKET AND SELL ELITES CBD PRODUCT LINE WITHIN THE UNITED STATES

    SUNRISE, Fla., April 30, 2019 -- Profile Solutions, Inc. (OTC Pink: PSIQ) announced today that its wholly owned subsidiary, Elite Products International, Inc. (“Elite”), has.

  • CNW Group

    Cannara Biotech Reports Q2 2019 Results

    Cannara Biotech Reports Q2 2019 Results

  • CNW Group

    Cannara Biotech Subsidiary Global shopCBD.com Raises in Excess of $8.8 Million to Fuel U.S. Hemp-CBD E-Commerce Platform

    With the recent passing of the 2018 Farm Bill in the U.S., CBD represents a developing sector with many vendors seeking national reach to U.S. customers. ShopCBD.com's strategy is to offer a wide variety of products from leading CBD brands, with competitive pricing and delivery times across the U.S. The rise in popularity for CBD products is driven by consumers seeking natural-based health & wellness solutions to treat various ailments from inflammation, anxiety to insomnia amongst many others.

  • CNW Group

    Cannara Biotech Announces Expansion of Phase 1 Build-Out and Board of Directors Update

    MONTREAL , March 14, 2019 /CNW/ - Cannara Biotech Inc. ("Cannara" or the "Company") (LOVE.CN) (8CB.F), a vertically integrated cannabis company in the making focused on cultivation and cannabis-infused products, today announced an expansion of the Phase 1 build-out of Cannara's facility from 130,000 to 170,000 square feet. As a result, the license application at Cannara's Farnham , in process with Health Canada, has been modified accordingly. Separately, Besar Xhelili has resigned from the Company's Board of Directors to pursue other business interests.